GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Defence Therapeutics Inc (XCNQ:DTC) » Definitions » Total Equity

Defence Therapeutics (XCNQ:DTC) Total Equity : C$-2.30 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Defence Therapeutics Total Equity?

Defence Therapeutics's total equity for the quarter that ended in Dec. 2023 was C$-2.30 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Defence Therapeutics Total Equity Historical Data

The historical data trend for Defence Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Defence Therapeutics Total Equity Chart

Defence Therapeutics Annual Data
Trend Jun20 Jun21 Jun22
Total Equity
1.86 5.49 -0.39

Defence Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.93 -2.10 1.33 -0.44 -2.30

Defence Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Defence Therapeutics's Total Equity for the fiscal year that ended in Jun. 2022 is calculated as

Total Equity=Total Assets(Q: Jun. 2022 )-Total Liabilities(Q: Jun. 2022 )
=0.72-1.107
=-0.39

Defence Therapeutics's Total Equity for the quarter that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=0.669-2.964
=-2.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Defence Therapeutics Total Equity Related Terms

Thank you for viewing the detailed overview of Defence Therapeutics's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Defence Therapeutics (XCNQ:DTC) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Defence Therapeutics Inc (XCNQ:DTC) » Definitions » Total Equity
Comparable Companies
TSX:EPRX NEOE:MMED TSXV:NGEN TSX:BCT TSX:ONC XCNQ:MSET TSXV:ARCH TSXV:MIR TSXV:DMT TSX:HBP OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
DTCFF:USA DTC:Germany
Address
200 Burrard Street, Suite 1680, Vancouver, BC, CAN, V6C3L6
Website
https://www.defencetherapeutics.com
Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development.
Executives
Sarkis Meterissian Director